NeumoVigo I+i
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (2)
2024
-
Triple Therapy and Clinical Control in B+ COPD Patients: A Pragmatic, Prospective, Randomized Trial
Archivos de Bronconeumologia, Vol. 60, Núm. 7, pp. 417-422
2017
-
Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease
Journal of the American Medical Directors Association, Vol. 18, Núm. 12, pp. 1097.e11-1097.e24